These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38889301)

  • 1. Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST study.
    Miyazaki Y; Nakayamada S; Tanaka H; Hanami K; Fukuyo S; Kubo S; Miyagawa I; Yamaguchi A; Todoroki Y; Inoue Y; Ueno M; Tanaka Y
    Rheumatology (Oxford); 2024 Jun; ():. PubMed ID: 38889301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
    Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
    Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study.
    Ohkubo N; Miyazaki Y; Nakayamada S; Fukuyo S; Inoue Y; Satoh-Kanda Y; Tanaka H; Todoroki Y; Miyata H; Nagayasu A; Funada M; Kobayashi H; Sakai H; Kosaka S; Matsunaga S; Tomoyose Y; Nohara H; Tanaka Y
    Rheumatol Ther; 2024 Oct; 11(5):1303-1319. PubMed ID: 39120846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.
    Nakayama Y; Hashimoto M; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A
    Scand J Rheumatol; 2022 Nov; 51(6):431-440. PubMed ID: 34511031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
    Onishi A; Yamada H; Yamamoto W; Watanabe R; Hara R; Katayama M; Okita Y; Maeda Y; Amuro H; Son Y; Yoshikawa A; Hata K; Hashimoto M; Saegusa J; Morinobu A
    Rheumatology (Oxford); 2024 Nov; 63(11):3065-3073. PubMed ID: 37988163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.
    Nakayama Y; Watanabe R; Yamamoto W; Ebina K; Hirano T; Kotani T; Shiba H; Katayama M; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Murakami K; Murata K; Ito H; Tanaka M; Matsuda S; Morinobu A; Hashimoto M
    Rheumatology (Oxford); 2024 Feb; 63(2):349-357. PubMed ID: 37354495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study.
    Dua AB; Ford K; Fiore S; Pappas DA; Janak JC; Blachley T; Roberts-Toler C; Emeanuru K; Kremer JM; Kivitz A
    Rheumatol Ther; 2023 Dec; 10(6):1753-1768. PubMed ID: 37906399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
    Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis.
    Fang YF; Liu JR; Chang SH; Kuo CF; See LC
    Int J Rheum Dis; 2022 Nov; 25(11):1254-1262. PubMed ID: 35923107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L; Ingrid E; Sepriano A; Nikiphorou E; Østgård R; Lauper K; Grosse-Michaelis I; Kloppenburg M; Glintborg B; Liew DFL; Kragstrup TW
    Drug Saf; 2024 Nov; 47(11):1075-1093. PubMed ID: 39012469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.
    Shirasugi I; Onishi A; Nishimura K; Yamamoto W; Murakami K; Onizawa H; Maeda Y; Ebina K; Son Y; Amuro H; Katayama M; Hara R; Nagai K; Hiramatsu Y; Hashimoto M; Okano T; Maeda T; Hayashi S; Sendo S; Jinno S; Yamamoto Y; Yamada H; Ueda Y; Saegusa J
    Int J Rheum Dis; 2024 Mar; 27(3):e15097. PubMed ID: 38439176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
    Taylor PC; Chen YF; Pope J; Weinblatt M; Mysler E; Rubbert-Roth A; Jia B; Sun L; Liu Y; Holzkämper T; Tanaka Y
    Rheumatol Ther; 2023 Apr; 10(2):463-476. PubMed ID: 36662442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis.
    Mori S; Urata Y; Yoshitama T; Ueki Y
    RMD Open; 2021 May; 7(2):. PubMed ID: 33958440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Retention Rate and Safety of JAK Inhibitors in Rheumatoid Arthritis: Real Word Data from a Monocentric Cohort.
    Donzella D; Bellis E; Crepaldi G; Data V; Gatto M; Lomater C; Liperoti G; Marucco E; Saracco M; Iagnocco A
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930022
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis.
    Temmoku J; Miyata M; Suzuki E; Sumichika Y; Saito K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Hayashi S; Tachibana S; Maeda T; Yamashita M; Shirasugi I; Yamamoto Y; Yamada H; Okano T; Nishimura K; Ueda Y; Jinno S; Saegusa J; Yamamoto W; Murata K; Fujii T; Hata K; Yoshikawa A; Ebina K; Etani Y; Yoshida N; Amuro H; Hashimoto M; Hara R; Katayama M; Okano T; Kuroda R
    Rheumatology (Oxford); 2024 Nov; 63(11):3033-3041. PubMed ID: 37924201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.